About Alchemab Therapeutics
A proprietary platform for mining human antibody repertoires sits at the core of Alchemab Therapeutics, a clinical-stage biotechnology company working to identify novel drug targets and therapeutics by reverse engineering the biology of resilient patients. Rather than starting from disease biology alone, the approach begins with well-defined patient samples drawn from individuals who are susceptible to a condition yet remain protected from it, using deep B cell sequencing and computational analysis to identify convergent protective antibody responses across that population.
The platform is designed to surface drug candidates that conventional discovery programmes are unlikely to find, making it particularly well suited to hard-to-treat diseases where existing therapeutic options remain limited. Alchemab has built its initial pipeline around neurodegenerative conditions and oncology, two areas where unmet medical need remains high and mechanistic understanding of protective immunity is still emerging.
Access to the highly specialised patient samples that power the platform depends on a network of partnerships with patient representative groups, biobanks, industry partners, and academic institutions. These collaborations are central to the company's discovery model, ensuring that the antibody repertoire data feeding the computational analysis pipeline reflects genuine protective biological signals rather than population averages.
Alchemab is led by Chief Executive Officer Jane Osbourn, OBE, FMedSci, PhD, who brings substantial scientific and commercial experience from the biotech and pharmaceutical sector. The broader executive and scientific leadership team is described as combining deep domain expertise with an ambitious development agenda across the company's growing pipeline.
Further information is available at alchemab.com.
